Lpath Inc.
6335 Ferris Square
Suite A
San Diego,
CA 92121
United States - Map
Phone: 858-678-0800
Fax: 858-678-0900
Web Site: http://www.lpath.com
| Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutics to treat human diseases in the United States. The companys product-development program primarily includes ASONEP, a phase I clinical product for a humanized monoclonal antibody against sphingosine-1-phosphate for the treatment of cancer and multiple sclerosis, as well as other angiogenic-related diseases and inflammatory-oriented indications. It also develops iSONEP, a phase I product in the ocular formulation of Sonepcizumab for age-related macular degeneration, diabetic retinopathy, and glaucoma-related surgery; and Lpathomab, a monoclonal antibody against lysophosphatidic acid for the treatment of cancer, fibrosis, neuropathic pain, and fibrotic ocular diseases. The company was founded in 1997 and is based in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Scott R. Pancoast ,
Founder, Chief Exec. Officer, Pres |
N/A
| N/A | Mr. Gary J. G. Atkinson , 56
Chief Financial Officer, Principal Accounting Officer, VP and Sec. |
N/A
| N/A | Dr. William A. Garland Ph.D., 63
Advisor |
N/A
| N/A | Mr. Roger Sabbadini Ph.D., 62
Scientific Founder, Chief Scientific Officer and VP |
N/A
| N/A | Dr. Glenn L. Stoller MD, 45
Head of Ocular Division |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.23% Nasdaq 
Profile
